Hickey, Magali,Perry, Jason,Deaver, Daniel,Remenar, Julius,Vandiver, Jennifer
申请号：
NZ73304712
公开号：
NZ733047A
申请日:
2012.03.19
申请国别(地区):
NZ
年份:
2018
代理人:
摘要：
Disclosed is the use of a pharmaceutical composition comprising aripiprazole lauroxil of formula A-7 or aripiprazole cavoxil of formula A-4 in the manufacture of a medicament for the treatment of schizophrenia, bipolar disorder or depression in a subject in need thereof, wherein the pharmaceutical composition comprises (a) 20 – 30 weight percent compound aripiprazole lauroxil or aripiprazole cavoxil, (b) approximately 0.2 – 1 weight percent sorbitan laurate； (c) approximately 0.05 – 0.8 weight percent polysorbate 20； and (d) an aqueous vehicle； and wherein the medicament is provided in the form of an aqueous, flocculated, injectable suspension.
